Defibrotide, an antithrombotic drug, was previously shown to activate fibrinolysis. In order to elucidate the relationship between defibrotide treatment and fibrinolysis, ten atherosclerotic patients were given 1200 mg/day defibrotide intravenously for 7 days and then 400 mg/day intramuscularly for another 20 days. t-PA antigen assessed before and after venous occlusion was not affected by the treatment. Tissue PAI activity significantly decreased and t-PA activity, measured after venous occlusion, increased after 8 and 28 days of treatment; both these changes disappeared after defibrotide was discontinued. No particular side effects were detected throughout the investigation. The study suggests that defibrotide increases t-PA activity by reducing PAI activity.
INHIBITION OF TISSUE PLASMINOGEN-ACTIVATOR INHIBITOR BY DEFIBROTIDE IN ATHEROSCLEROTIC PATIENTS / Violi, Francesco; Ferro, Domenico; Alessandri, Cesare; Claudio, Quintarelli; Mirella, Saliola; Francesco, Balsano. - In: SEMINARS IN THROMBOSIS AND HEMOSTASIS. - ISSN 0094-6176. - 15:2(1989), pp. 226-229. [10.1055/s-2007-1002709]
INHIBITION OF TISSUE PLASMINOGEN-ACTIVATOR INHIBITOR BY DEFIBROTIDE IN ATHEROSCLEROTIC PATIENTS
VIOLI, Francesco;FERRO, Domenico;ALESSANDRI, Cesare;
1989
Abstract
Defibrotide, an antithrombotic drug, was previously shown to activate fibrinolysis. In order to elucidate the relationship between defibrotide treatment and fibrinolysis, ten atherosclerotic patients were given 1200 mg/day defibrotide intravenously for 7 days and then 400 mg/day intramuscularly for another 20 days. t-PA antigen assessed before and after venous occlusion was not affected by the treatment. Tissue PAI activity significantly decreased and t-PA activity, measured after venous occlusion, increased after 8 and 28 days of treatment; both these changes disappeared after defibrotide was discontinued. No particular side effects were detected throughout the investigation. The study suggests that defibrotide increases t-PA activity by reducing PAI activity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.